Show simple item record

dc.contributor.authorChamberlain, Samuel
dc.contributor.authorGrant, Jon E
dc.date.accessioned2018-10-03T04:43:26Z
dc.date.available2018-10-03T04:43:26Z
dc.date.issued2018-11
dc.identifier.issn0033-2917
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/283022
dc.description.abstractBACKGROUND: Impulsivity and compulsivity are central to understanding a range of psychiatric disorders but also to understanding the spectrum of normative human behavior. It was recently shown that separable latent phenotypes of impulsivity and compulsivity could be fractionated. The possible genetic contributions to these latent phenotypes have yet to be elicited. The catechol-o-methyl transferase (COMT) Val158Met polymorphism (rs4680) regulates cortical dopamine degradation and is a key area of interest in this context. METHODS: COMT Val158Met polymorphism status was obtained from a random subset (n = 258) of young adults from an established cohort, for whom latent phenotype scores were previously reported. Differences in latent phenotype scores were explored between COMT groups using analysis of variance (ANOVA) and post-hoc t tests. RESULTS: The Val-Val subgroup exhibited significantly elevated compulsivity scores compared to both other groups. Impulsivity scores did not differ significantly as a function of COMT Val158Met polymorphism status. CONCLUSIONS: These results suggest that the COMT polymorphism, and by implication cortical dopamine degradation, influences the expression of a trans-diagnostic compulsivity phenotype, even accounting for possible confounding effects of impulsivity.
dc.description.sponsorshipWellcome Trust
dc.format.mediumPrint-Electronic
dc.languageeng
dc.publisherCambridge University Press (CUP)
dc.subjectHumans
dc.subjectCatechol O-Methyltransferase
dc.subjectCohort Studies
dc.subjectImpulsive Behavior
dc.subjectCompulsive Behavior
dc.subjectAdult
dc.subjectYoung Adult
dc.titleSelective role for the COMT polymorphism in a trans-diagnostic compulsivity phenotype.
dc.typeArticle
prism.endingPage2627
prism.issueIdentifier15
prism.publicationDate2018
prism.publicationNamePsychol Med
prism.startingPage2626
prism.volume48
dc.identifier.doi10.17863/CAM.30386
dcterms.dateAccepted2018-07-27
rioxxterms.versionofrecord10.1017/S0033291718002180
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2018-11
dc.contributor.orcidChamberlain, Samuel [0000-0001-7014-8121]
dc.identifier.eissn1469-8978
rioxxterms.typeJournal Article/Review
pubs.funder-project-idWellcome Trust (110049/Z/15/Z)
cam.issuedOnline2018-08-24
rioxxterms.freetoread.startdate2019-08-24


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record